Introduction: DAT-SPECT imaging is approved as a diagnostic tool for the evaluation of suspected Parkinsonian syndromes, but the FDA-approved package insert lists 16 potential drugs that may interfere with the image obtained. The clinical impact of these drugs on imaging results has not been established. This study aimed to determine the accuracy of DAT-SPECT imaging in assessing presynaptic dopaminergic denervation in the setting of these drugs. Methods: This is a retrospective chart review of patients at a single center who underwent DAT-SPECT imaging while taking “contraindicated” drugs between December 2012 and December 2022. Results: A total of 1,224 charts were screened, and 153 (12.5%) charts met the inclusion criteria. Bupropion (32%, n = 49) and sertraline (26%, n = 40) were the most common contraindicated drugs. The false-positive rate was 9.2%. Conclusion: This retrospective analysis supports the concern that certain drugs may interfere with DAT-SPECT imaging results, leading to potential false positives. This has implications for how clinicians interpret DAT-SPECT imaging in patients taking these medications and whether they should advise patients to stop these medications before a scan is performed.

Journal Section:
Brief Report
Keywords:
Parkinson’s disease, DAT-SPECT imaging, Dopamine, Movement disorders, Parkinsonian disorders
1.
DeMaagd
G
,
Philip
A
.
Parkinson’s disease and its management: Part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis
.
P T
.
2015
;
40
(
8
):
504
–
32
.
Google Scholar
PubMed
 
2.
Bega
D
,
Kuo
PH
,
Chalkidou
A
,
Grzeda
MT
,
Macmillan
T
,
Brand
C
, et al.
Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis
.
NPJ Parkinsons Dis
.
2021
;
7
(
1
):
43
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Jakobson Mo
S
,
Linder
J
,
Forsgren
L
,
Riklund
K
.
Accuracy of visual assessment of dopamine transporter imaging in early parkinsonism
.
Mov Disord Clin Pract
.
2014
;
2
(
1
):
17
–
23
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Seifert
KD
,
Wiener
JI
.
The impact of DaTscan on the diagnosis and management of movement disorders: a retrospective study
.
Am J Neurodegener Dis
.
2013
;
2
(
1
):
29
–
34
.
Google Scholar
PubMed
 
6.
Booij
J
,
Kemp
P
.
Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs
.
Eur J Nucl Med Mol Imaging
.
2008
;
35
(
2
):
424
–
38
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Chahid
Y
,
Sheikh
ZH
,
Mitropoulos
M
,
Booij
J
.
A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice
.
Eur J Nucl Med Mol Imaging
.
2023
;
50
(
7
):
1974
–
87
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Suwijn
SR
,
van Boheemen
CJ
,
de Haan
RJ
,
Tissingh
G
,
Booij
J
,
de Bie
RM
.
The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review
.
EJNMMI Res
.
2015
;
5
:
12
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.